To Cite:
Alavian
S M, Imanieh
M H, Imanieh
M H. Predictive Factors in the Incidence of Cirrhosis in Chronic Hepatitis B Virus Infections,
Hepat Mon.
Online ahead of Print
; 16(5):e58756.
doi: 10.5812/hepatmon.34790.
1.
Alavian SM. Hepatitis B virus infection in Iran; Changing the epidemiology. ARCHCID. 2010; 5(1): 51-61
2.
Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009; 373(9663): 582-92[DOI]
3.
Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004; 11(2): 97-107[PubMed]
4.
Alavian SM, Hajarizadeh B, Ahmadzad-Asl M, Kabir A, Lankarani KB. Hepatitis B Virus Infection in Iran: A Systematic Review. Hepat Mon. 2008; 8(4): 281-94
5.
Croagh CM, Desmond PV, Bell SJ. Genotypes and viral variants in chronic hepatitis B: A review of epidemiology and clinical relevance. World J Hepatol. 2015; 7(3): 289-303[DOI][PubMed]
6.
Bahramali G,
Sadeghizadeh M,
Amini-Bavil-Olyaee S,
Alavian SM,
Behzad-Behbahani A,
Adeli A,
et al.
Clinical, virologic and phylogenetic features of hepatitis B infection in Iranian patients. World J Gastroenterol. 2008; 14(35): 5448-53[PubMed]
7.
Sunbul M. Hepatitis B virus genotypes: global distribution and clinical importance. World J Gastroenterol. 2014; 20(18): 5427-34[DOI][PubMed]
8.
Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008; 48(2): 335-52[DOI][PubMed]
9.
Yuen MF,
Yuan HJ,
Wong DK,
Yuen JC,
Wong WM,
Chan AO,
et al.
Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut. 2005; 54(11): 1610-4[DOI][PubMed]
10.
European Association For The Study Of The L. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57(1): 167-85[DOI][PubMed]
11.
Liaw YF,
Kao JH,
Piratvisuth T,
Chan HL,
Chien RN,
Liu CJ,
et al.
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012; 6(3): 531-61[DOI][PubMed]
12.
Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016; 63(1): 261-83[DOI][PubMed]
14.
Sali S, Alavian SM, Foster GR, Keyvani H, Mehrnoosh L, Mohammadi N. Influencing Factors on the Outcome and Prognosis of Patients With HBV Infction: Seven Years Follow-up. Hepat Mon. 2013; 13(7): 8743[DOI]
15.
Lee MH,
Yang HI,
Liu J,
Batrla-Utermann R,
Jen CL,
Iloeje UH,
et al.
Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology. 2013; 58(2): 546-54[DOI][PubMed]
16.
Liu CJ, Kao JH, Chen DS. Therapeutic implications of hepatitis B virus genotypes. Liver Int. 2005; 25(6): 1097-107[DOI][PubMed]
17.
Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007; 16(4): 403-6[PubMed]
18.
Askarian M, Mansour Ghanaie R, Karimi A, Habibzadeh F. Infectious diseases in Iran: a bird's eye view. Clin Microbiol Infect. 2012; 18(11): 1081-8[DOI][PubMed]
19.
Poh Z, Goh BB, Chang PE, Tan CK. Rates of cirrhosis and hepatocellular carcinoma in chronic hepatitis B and the role of surveillance: a 10-year follow-up of 673 patients. Eur J Gastroenterol Hepatol. 2015; 27(6): 638-43[DOI][PubMed]
20.
Iloeje UH,
Yang HI,
Su J,
Jen CL,
You SL,
Chen CJ,
et al.
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006; 130(3): 678-86[DOI][PubMed]
21.
Park BK,
Park YN,
Ahn SH,
Lee KS,
Chon CY,
Moon YM,
et al.
Long-term outcome of chronic hepatitis B based on histological grade and stage. J Gastroenterol Hepatol. 2007; 22(3): 383-8[DOI][PubMed]
22.
Sagnelli E,
Stroffolini T,
Mele A,
Imparato M,
Sagnelli C,
Coppola N,
et al.
Impact of comorbidities on the severity of chronic hepatitis B at presentation. World J Gastroenterol. 2012; 18(14): 1616-21[DOI][PubMed]
23.
Cadranel JF,
Lahmek P,
Causse X,
Bellaiche G,
Bettan L,
Fontanges T,
et al.
Epidemiology of chronic hepatitis B infection in France: risk factors for significant fibrosis--results of a nationwide survey. Aliment Pharmacol Ther. 2007; 26(4): 565-76[DOI][PubMed]
24.
Amini N, Alavian SM, Kabir A, Saiedi Hosseini SY, Aalaei Andabili SH. Clinical Features and Seroepidemiology of Anti-HDV Antibody in patients With Chronic Hepatitis B Virus Infection in Iran: A Meta-Analysis. Hepat Mon. 2011; 11(12): 960-7[DOI][PubMed]
25.
Alavian SM, Alavian SH. Hepatitis D Virus Infection; Iran, Middle East and Central Asia. Hepat Mon. 2005; 5(4): 137-43
26.
Gu XH,
Chen Z,
Dai RY,
Zhang ML,
Tang HM,
Chen LB,
et al.
Analysis on the clinical features of 507 HDV-infected patients. Cell Biochem Biophys. 2014; 70(3): 1829-32[DOI][PubMed]
27.
Rosina F,
Conoscitore P,
Cuppone R,
Rocca G,
Giuliani A,
Cozzolongo R,
et al.
Changing pattern of chronic hepatitis D in Southern Europe. Gastroenterology. 1999; 117(1): 161-6[PubMed]
28.
Hsu YS,
Chien RN,
Yeh CT,
Sheen IS,
Chiou HY,
Chu CM,
et al.
Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002; 35(6): 1522-7[DOI][PubMed]
29.
Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med. 2004; 116(12): 829-34[DOI][PubMed]
30.
Lin SM,
Yu ML,
Lee CM,
Chien RN,
Sheen IS,
Chu CM,
et al.
Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol. 2007; 46(1): 45-52[DOI][PubMed]
31.
Jang JW,
Lee YC,
Kim MS,
Lee SY,
Bae SH,
Choi JY,
et al.
A 13-year longitudinal study of the impact of double mutations in the core promoter region of hepatitis B virus on HBeAg seroconversion and disease progression in patients with genotype C chronic active hepatitis. J Viral Hepat. 2007; 14(3): 169-75[DOI][PubMed]
32.
Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis. 2006; 26(2): 130-41[DOI][PubMed]
33.
Zarski JP,
Marcellin P,
Leroy V,
Trepo C,
Samuel D,
Ganne-Carrie N,
et al.
Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. J Hepatol. 2006; 45(3): 355-60[DOI][PubMed]
34.
Kao JH, Chen PJ, Chen DS. Recent advances in the research of hepatitis B virus-related hepatocellular carcinoma: epidemiologic and molecular biological aspects. Adv Cancer Res. 2010; 108: 21-72[DOI][PubMed]
35.
Mazzella G,
Saracco G,
Festi D,
Rosina F,
Marchetto S,
Jaboli F,
et al.
Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Am J Gastroenterol. 1999; 94(8): 2246-50[DOI][PubMed]
36.
Croagh CM, Lubel JS. Natural history of chronic hepatitis B: phases in a complex relationship. World J Gastroenterol. 2014; 20(30): 10395-404[DOI][PubMed]
37.
Ansari N, Makvandi M, Samarbaf-Zadeh AR. Hepatitis B virus Genotyping Among Patients With Cirrhosis. Jundishapur J Microbiol. 2015; 8(3)[DOI][PubMed]
38.
Hayashi H, Beppu T, Shirabe K, Maehara Y, Baba H. Management of thrombocytopenia due to liver cirrhosis: a review. World J Gastroenterol. 2014; 20(10): 2595-605[DOI][PubMed]
39.
Iannacone M,
Sitia G,
Isogawa M,
Marchese P,
Castro MG,
Lowenstein PR,
et al.
Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat Med. 2005; 11(11): 1167-9[DOI][PubMed]
40.
Kodama T,
Takehara T,
Hikita H,
Shimizu S,
Li W,
Miyagi T,
et al.
Thrombocytopenia exacerbates cholestasis-induced liver fibrosis in mice. Gastroenterology. 2010; 138(7): 2487-98[DOI][PubMed]
41.
Mohamadnejad M,
Montazeri G,
Fazlollahi A,
Zamani F,
Nasiri J,
Nobakht H,
et al.
Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-virus related liver disease. Am J Gastroenterol. 2006; 101(11): 2537-45[DOI][PubMed]
42.
Wong GL,
Wong VW,
Choi PC,
Chan AW,
Chim AM,
Yiu KK,
et al.
Evaluation of alanine transaminase and hepatitis B virus DNA to predict liver cirrhosis in hepatitis B e antigen-negative chronic hepatitis B using transient elastography. Am J Gastroenterol. 2008; 103(12): 3071-81[DOI][PubMed]
43.
Karbasi A, Bafandeh B, Alavian SM, Saburi A. Can Viral Load Predict Liver Histology in Patients With Chronic Hepatitis B? Int J Travel Med Global Health. 2015; 3(1): 19-21[DOI]
44.
Shao J,
Wei L,
Wang H,
Sun Y,
Zhang LF,
Li J,
et al.
Relationship between hepatitis B virus DNA levels and liver histology in patients with chronic hepatitis B. World J Gastroenterol. 2007; 13(14): 2104-7[PubMed]
45.
Zacharakis G,
Koskinas J,
Kotsiou S,
Tzara F,
Vafeiadis N,
Papoutselis M,
et al.
The role of serial measurement of serum HBV DNA levels in patients with chronic HBeAg(-) hepatitis B infection: association with liver disease progression. A prospective cohort study. J Hepatol. 2008; 49(6): 884-91[DOI][PubMed]
46.
Buster EH,
Hansen BE,
Lau GK,
Piratvisuth T,
Zeuzem S,
Steyerberg EW,
et al.
Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology. 2009; 137(6): 2002-9[DOI][PubMed]
Readers' Comments